Key Drivers
- Cash generation
- Heavy leverage
- Weak quarter
AIAI Summary
HROW now looks like a proof-of-execution story rather than a pure growth name, with the key question being whether Q2/Q3 can show that strong prescription demand converts into clean revenue and positive cash flow after reimbursement and gross-to-net noise, because weak Q1, heavy leverage, and a demanding valuation leave little room for further misses.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash generation
- •Heavy leverage
- •Weak quarter
HROW posted strong prior-year cash generation and adequate liquidity, but its heavy leverage, weak tangible equity, and sharp quarterly deterioration in profitability and cash flow make the current valuation look stretched.
Price Behavior
Key Price Behavior Insights:
- •Support break
- •Weak bounce
- •Overhead resistance
Over the last month, HROW broke down from a stable high-30s/low-40s range to 31.21 after a sharp 2026-05-12 selloff, with only a modest bounce so far and 38-40 now acting as resistance while 29-31 remains key support.
Sharp drop from $38.04 to $29.03 on 2026-05-12
Sentiment & News
Key News Insights:
- •Revenue miss
- •Guidance intact
- •Legal overhang
Harrow's Q1 miss and VEVYE revenue hiccup pressured results, but the company reaffirmed full-year guidance amid strong prescription growth and now faces a securities-law probe.
The stock is likely to stay volatile as investors weigh underlying product momentum against execution concerns and the new investigation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings